Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance/University of Washington, Seattle, WA 98109, USA.
J Natl Compr Canc Netw. 2010 Jul;8(7):815-21. doi: 10.6004/jnccn.2010.0058.
Recent trials have shown a benefit with maintenance therapy after 4 to 6 cycles of chemotherapy. These trials have shown improvement in progression-free survival using agents approved as second-line therapy in non-small cell lung cancer. Trials using erlotinib and pemetrexed showed improvement in overall survival. Consideration of trial design is critical for the interpretation of these results. Data on quality of life and cost have not been presented, but will ultimately be important in evaluating the usefulness of these approaches.
最近的试验表明，在化疗 4 到 6 个周期后进行维持治疗有获益。这些试验表明，使用已批准用于非小细胞肺癌二线治疗的药物可以改善无进展生存期。使用厄洛替尼和培美曲塞的试验显示总生存期有所改善。对于这些结果的解释，试验设计的数据至关重要。关于生活质量和成本的数据尚未公布，但最终对于评估这些方法的有用性非常重要。
